Top

Published in:

Open Access 01-12-2016 | Review

Role of BAF60a/BAF60c in chromatin remodeling and hepatic lipid metabolism

Authors: Ping Zhang, Lulu Li, Zhengxi Bao, Feiruo Huang

Published in: Nutrition & Metabolism | Issue 1/2016

Abstract

The switching defective/sucrose non-fermenting (SWI/SNF) complexes play an important role in hepatic lipid metabolism regulating both transcriptional activation and repression. BAF60a is a core subunit of the SWI/SNF chromatin-remodeling complexes that activates the transcription of fatty acid oxidation genes during fasting/glucagon. BAF60c, another subunit of SWI/SNF complexes, is recruited to form the lipoBAF complex that activates lipogenic genes, promoting lipogenesis and increasing the triglyceride level in response to feeding/insulin. Interestingly, hepatocytes located in the periportal and perivenous zones of the liver display a remarkable heterogeneity in the activity of various enzymes, metabolic functions and gene expression. Especially, fatty-acid oxidation was shown to be mostly periportal, whereas lipogenesis was mostly perivenous. Therefore, the present review highlights the role of of SWI/SNF regulating lipid metabolism under nutritional and hormonal control, which may be associated with hepatocyte heterogeneity.

Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Path Microbiol Dis. 2010;5:145–71.CrossRef

Younossi ZM. Current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28:2–12.CrossRef

Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev. 2008;60:311–57.CrossRef

Lu Y, Liu X, Jiao Y, Xiong X, Wang E, Wang X, et al. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest. 2014;124:3501.CrossRef

Wong RHF. Regulation of lipogenic gene transcription during fasting and feeding/insulin: Role of USF, SREBP-1c, and BAF60c. Electron Thesis Dissertations. 2010.

Griffin MJ, Wong RH, Pandya N, Sul HS. Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter. J Biol Chem. 2007;282:5453–67.CrossRef

Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615–22.CrossRef

Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARα) in the cellular fasting response: the PPARa-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA. 1999;96:7473–8.CrossRef

Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009;138:476–88.CrossRef

10.

Gebhardt R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol Ther. 1992;53:275–354.CrossRef

11.

Braeuning A, Ittrich C, Köhle C, Hailfinger S, Bonin M, Buchmann A, et al. Differential gene expression in periportal and perivenous mouse hepatocytes. FEBS J. 2006;273:5051–61.CrossRef

12.

Guzman M, Castro J. Zonation of fatty acid metabolism in rat liver. Biochem J. 1989;264:107–13.CrossRef

13.

Katz N, Fischer W, Ick M. Heterogenous distribution of ATP citrate lyase in rat liver parenchyma. Eur J Biochem. 1983;130:297–301.CrossRef

14.

Katz N, Fischer W, Giffhorn S. Distribution of enzymes of fatty acid and ketone body metabolism in periportal and perivenous rat liver tissue. Eur J Biochem. 1983;135:103–7.CrossRef

15.

Katz N, Ruschenburg I, Giffhorn S. The pubertal sex specific development of zonation of fatty acid synthase in rat liver. Acta Histochem. 1985;Suppl. 32:111–3.

16.

Katz N, Thiele J, Giffhorn-Katz S. Zonal distribution of fatty acid synthase in liver parenchyma of male and female rats. Eur J Biochem. 1989;180:185–9.CrossRef

17.

Li S, Liu C, Li N, Hao T, Han T, Hill DE, et al. Genome-wide coactivation analysis of PGC-1α identifies BAF60a as a regulator of hepatic lipid metabolism. Cell Metab. 2008;8:105–17.CrossRef

18.

Wang Y, Wong RHF, Tang T, Hudak CS, Yang D, Duncan RE, et al. Phosphorylation and recruitment of BAF60c in chromatin remodeling for lipogenesis in response to insulin. Mol Cell. 2013;49:283–97.CrossRef

19.

Carlson M, Osmond BC, Botstein D. Mutants of yeast defective in sucrose utilization. Genetics. 1981;98:25–40.

20.

Neigeborn L, Carlson M. Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. Genetics. 1984;108:845–58.

21.

Neigeborn L, Carlson M. Mutations causing constitutive invertase synthesis in yeast: genetic interactions with snf mutations. Genetics. 1987;115:247–53.

22.

Muratcioglu S, Presman DM, Pooley JR, Grøntved L, Hager GL, Nussinov R, et al. Structural Modeling of GR Interactions with the SWI/SNF Chromatin Remodeling Complex and C/EBP. Biophys J. 2015;109:1227–39.CrossRef

23.

Chen J, Archer TK. Regulating SWI/SNF subunit levels via protein-protein interactions and proteasomal degradation: BAF155 and BAF170 limit expression of BAF57. Mol Cell Biol. 2005;25:9016–27.CrossRef

24.

Lickert H, Takeuchi JK, von Both I, Walls JR, McAuliffe F, Adamson SL, et al. Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. Nature. 2004;432:107–12.CrossRef

25.

Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev. 1996;10:2117–30.CrossRef

26.

Carlson M, Laurent BC. The SNF/SWI family of global transcriptional activators. Curr Opin Cell Biol. 1994;6:396–402.CrossRef

27.

Holstege FC, Jennings EG, Wyrick JJ, Lee TI, Hengartner CJ, Green MR, et al. Dissecting the regulatory circuitry of a eukaryotic genome. Cell. 1998;95:717–28.CrossRef

28.

Martens JA, Winston F. Recent advances in understanding chromatin remodeling by Swi/Snf complexes. Curr Opin Genet Dev. 2003;13:136–42.CrossRef

29.

Kwon H, Imbalzano AN, Khavari PA, Kingston RE, Green MR. Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature. 1994;370:477–81.CrossRef

30.

Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 2011;21:396–420.CrossRef

31.

Kwon CS, Wagner D. Unwinding chromatin for development and growth: a few genes at a time. Trends Genet. 2007;23:403–12.CrossRef

32.

Roberts CW, Orkin SH. The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer. 2004;4:133–42.CrossRef

33.

Banerjee R, Bultman SJ, Holley D, Hillhouse C, Bain JR, Newgard CB, et al. Non-targeted metabolomics of Brg1/Brm double-mutant cardiomyocytes reveals a novel role for SWI/SNF complexes in metabolic homeostasis. Metabolomics. 2015;11:1287–301.CrossRef

34.

Trotter KW, Archer TK. The BRG1 transcriptional coregulator. Nucl Recept Signal. 2008;6:e004.

35.

Puri PL, Mercola M. BAF60 A, B, and Cs of muscle determination and renewal. Genes Dev. 2012;26:2673–83.CrossRef

36.

Narlikar GJ, Sundaramoorthy R, Owen-Hughes T. Mechanisms and functions of ATPdependent chromatin-remodeling enzymes. Cell. 2013;154:490–503.CrossRef

37.

Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene. 2007;26:7058–66.CrossRef

38.

Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol. 2001;186:136–45.CrossRef

39.

Bevilacqua A, Willis MS, Bultman SJ. SWI/SNF chromatin-remodeling complexes in cardiovascular development and disease. J Cardiovasc Pharmacol. 2014;23:85–91.

40.

Chang CP, Bruneau BG. Epigenetics and cardiovascular development. Annu Rev Physiol. 2012;74:41–68.CrossRef

41.

Meng ZX, Li S, Wang L, Ko HJ, Lee Y, Jung DY, et al. Baf60c drives glycolytic metabolism in the muscle and improves systemic glucose homeostasis through Deptor-mediated Akt activation. Nat Med. 2013;19:640–5.CrossRef

42.

Sudarsanam P, Winston F. The Swi/Snf family: nucleosome-remodeling complexes and transcriptional control. Trends Genet. 2000;16:345–51.CrossRef

43.

Meng ZX, Wang L, Xiao Y, Lin JD. The Baf60c/Deptor pathway links skeletal muscle inflammation to glucose homeostasis in obesity. Diabetes. 2014;63:1533–45.CrossRef

44.

Hsiao PW, Fryer CJ, Trotter KW, Wang W, Archer TK. BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol. 2003;23:6210–20.CrossRef

45.

Tao W, Chen S, Shi G, Guo J, Xu Y, Liu C. SWItch/sucrose nonfermentable (SWI/SNF) complex subunit BAF60a integrates hepatic circadian clock and energy metabolism. Hepatology. 2011;54:1410–20.CrossRef

46.

Ito T, Yamauchi M, Nishina M, Yamamichi N, Mizutani T, Ui M, et al. Identification of SWI/SNF complex subunit BAF60a as a determinant of the transactivation potential of Fos/Jun dimers. J Biol Chem. 2001;276:2852–7.CrossRef

47.

Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 2009;23:1313–26.CrossRef

48.

Meng ZX, Wang L, Chang L, Sun J, Bao J, Li Y, et al. A Diet-Sensitive BAF60a-Mediated Pathway Links Hepatic Bile Acid Metabolism to Cholesterol Absorption and Atherosclerosis. Cell Rep. 2015;13:1658–69.CrossRef

49.

Debril MB, Gelman L, Fayard E, Annicotte JS, Rocchi S, Auwerx J. Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subuni.t. J Biol Chem. 2004;279:16677–86.CrossRef

50.

Takeuchi JK, Lickert H, Bisgrove BW, Sun X, Yamamoto M, Chawengsaksophak K, et al. Baf60c is a nuclear Notch signaling component required for the establishment of left-right asymmetry. Proc Natl Acad Sci U S A. 2007;104:846–51.CrossRef

51.

Forcales SV, Albini S, Giordani L, Malecova B, Cignolo L, Chernov A, et al. Signaldependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. EMBO J. 2012;31:301–16.CrossRef

52.

Simone C, Forcales SV, Hill DA, Imbalzano AN, Latella L, Puri PL. p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat Genet. 2004;36:738–43.CrossRef

53.

Colnot S, Perret C. Molecular pathology of liver diseases, Liver zonation. Springer US. 2011;5:7–16.

54.

Torre C, Perret C, Colnot S. Int J. Biochem Transcription dynamics in a physiological process: β-catenin signaling directs liver metabolic zonation. Cell Biol. 2011;43:271–8.

55.

Jungermann K, Katz N. Functional specialization of different hepatocyte populations. Physiol Rev. 1989;69:708–64.

56.

Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr. 1996;16:179–203.CrossRef

57.

Tosh D, George K, Alberti MM, Agius L. Clofibrate induces carnitine acyltransferases in periportal and perivenous zones of rat liver and does not disturb the acinar zonation of gluconeogenesis. BBA-General Subjects. 1989;992:245–50.CrossRef

58.

Jungermann K. Functional heterogeneity of periportal and perivenous hepatocytes. Enzyme. 1985;35:161–80.

59.

Haussinger D. Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur J Biochem. 1983;133:269–75.CrossRef

60.

Kari FW, Yoshihara H, Thurman RG. Urea synthesis from ammonia in periportal and pericentral regions of the liver lobule. Eur J Biochem. 1987;163:1–7.CrossRef

61.

Görgens HW, Hildebrand R, Haubitz I. Distribution pattern of alanine aminotransferase activity in rat live. Histochemistry. 1988;88:383–6.

62.

Katz N, Teutsch HF, Jungermann K, Sasse D. Heterogeneous reciprocal localization of fructose-1,6-bisphosphatase and of glucokinase in microdissected periportal and perivenous rat liver tissue. FEBS Lett. 1977;83:272–6.CrossRef

63.

Haussinger D, Lamers WH, Moorman AF. Hepatocyte heterogeneity in the metabolism of amino acids and ammonia. Enzyme. 1992;46:72–93.

64.

Gebhardt R, Lindros K, Lamers WH, Moorman AF. Hepatocellular heterogeneity in ammonia metabolism: demonstration of limited colocalization of carbamoylphosphate synthetase and glutamine synthetase. Eur J Cell Biol. 1991;56:464–7.

65.

Gebhardt R, Baldysiak-Figiel A, Krugel V, Ueberham E, Gaunitz F. Hepatocellular expression of glutamine synthetase: an indicator of morphogen actions as master regulators of zonation in adult liver. Prog Histochem Cytochem. 2007;41:201–66.CrossRef

66.

Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001;21:193–230.CrossRef

67.

Hashimoto T, Fujita T, Usuda N, Cook W, Qi C, Peters JM, et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem. 1999;274:19228–36.CrossRef

68.

Bartlett K, Eaton S. Mitochondrial β-oxidation. Eur J Biochem. 2004;271:462–9.CrossRef

69.

Ramsay RR. The carnitine acyltransferases: modulators of acyl-CoA-dependent reactions. Biochem Soc Trans. 2000;28:182–6.CrossRef

70.

Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101:335–47.CrossRef

71.

Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J Lipid Res. 2009;50:138–43.CrossRef

72.

Chang SI, Hammes GG. Structure and mechanism of action of a multifunctional enzyme: fatty acid synthase. Acc Chem Res. 1990;23:363–9.CrossRef

73.

Wang Y, Voy BJ, Urs S, Kim S, Soltani-Bejnood M, Quigley N, et al. The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. J Nutr. 2004;134:1032–8.

74.

Rioux V, Catheline D, Legrand P. In rat hepatocytes, myristic acid occurs through lipogenesis, palmitic acid shortening and lauric acid elongation. Animal. 2007;1:820–6.CrossRef

75.

Evans JL, Quistorff B, Witters LA. Zonation of hepatic lipogenic enzymes identified by dual-digitonin-pulse perfusion. Biochem J. 1989;259:821–9.CrossRef

76.

Wang Y, Lin Q, Zheng P, Li L, Bao Z, Huang F. Effects of eicosapentaenoic acid and docosahexaenoic acid on chylomicron and VLDL synthesis and secretion in Caco-2 cells. BioMed Res Int. 2014.

77.

Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell. 1993;75:187–97.CrossRef

78.

Wong RH, Sul HS. Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective. Curr Opin Pharmacol. 2010;10:684–91.CrossRef

79.

Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–31.CrossRef

80.

Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie. 2005;87:81–6.CrossRef

81.

Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86:839–48.CrossRef

82.

Moon YA, Shah NA, Mohapatra S, Warrington JA, Horton JD. Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J Biol Chem. 2001;276:45358–66.CrossRef

83.

Edwards PA, Tabor D, Kast HR, Venkateswaran A. Regulation of gene expression by SREBP and SCAP. Biophys Acta. 2000;1529:103–13.

84.

Casado M, Vallet VS, Kahn A, Vaulont S. Essential role in vivo of upstream stimulatory factors for a normal dietary response of the fatty acid synthase gene in the liver. J Biol Chem. 1999;274:2009–13.CrossRef

85.

Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434:113–8.CrossRef

86.

Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A. 1994;91:11012–6.CrossRef

87.

Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem. 1998;273:5678–84.CrossRef

88.

Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem. 1997;272:27307–12.CrossRef

89.

Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem. 1998;273:16710–4.CrossRef

90.

Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354–66.

91.

Pyper S, Reddy JK. PPARα: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002.CrossRef

92.

Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003;3:561–72.CrossRef

93.

McEwan IJ. Nuclear receptors: one big family. Methods Mol Biol. 2009;505:3–18.CrossRef

94.

Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Enorcri Rev. 1999;20:649–88.

95.

Tontonoz P, Speigelman BM. Fat and beyond: the diverse biology of PPAR gamma. Annu Rev Biochem. 2008;77:289–312.CrossRef

96.

Houten SM, Wanders RJ, Inherit J. A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. Metab Dis. 2010;33:469–77.

97.

Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489–98.CrossRef

98.

Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, et al. PGC-1 promotes insulin resistance in liver through PPARα-dependent induction of TRB-3. Nat Med. 2004;10:530–4.CrossRef

99.

Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413:131–8.CrossRef

100.

Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000;20:1868–76.CrossRef

101.

Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92:829–39.CrossRef

102.

Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, et al. PGC-1α deficient mice exhibit multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control, and hepatic steatosis. PLoS Biol. 2005;3:672–87.CrossRef

103.

Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1α. Cell Metab. 2006;3:429–38.CrossRef

104.

Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. Nature. 2009;458:1056–60.CrossRef

105.

Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD⁺ levels dictate cell survival. Cell. 2007;130:1095–107.CrossRef

106.

Dominy JE, Lee Y, Gerhart-Hines Z, Puigserver P. Nutrient-dependent regulation of PGC-1α’s acetylation state and metabolic function through the enzymatic activities of SIRT1/GCN5. BBA-Proteins Proteomics. 2010;1804:1676–83.CrossRef

107.

Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J Biol Chem. 2005;280:16456–60.CrossRef

108.

Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. EMBO J. 2007;26:1913–23.CrossRef

109.

Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A. 2009;106:10853–8.CrossRef

110.

Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426–37.CrossRef

111.

Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1α pathway. Proc Natl Acad Sci U S A. 2010;107:12553–8.CrossRef

112.

Chen S, Ding Y, Zhang Z, Wang H, Liu C. Hyperlipidaemia impairs the circadian clock and physiological homeostasis of vascular smooth muscle cells via the suppression of Smarcd1. J Physiol. 2014;233:159–69.

113.

Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Netherlands Heart J. 2007;15:100–8.CrossRef

114.

Liu C, Li S, Liu T, Borjigin J, Lin JD. Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism. Nature. 2007;447:477–81.CrossRef

115.

Corton JC, Lapinskas PJ, Gonzalez FJ. Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat Res Fund Mol M. 2000;448:139–51.CrossRef

116.

Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T. Peroxisome proliferator-activated receptor a controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem. 1998;273:31581–3158.CrossRef

117.

Leone TC, Cresci S, Carter ME, Zhang Z, Lala DS, Strauss AW, et al. The human medium chain acyl-CoA dehydrogenase gene promoter consists of a complex arrangement of nuclear receptor response elements and Sp1 binding sites. J Biol Chem. 1995;270:16308–14.CrossRef

118.

Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor a-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. Biol Chem. 1998;273:29577–85.CrossRef

119.

Sack MN, Disch DL, Rockman HA, Kelly DP. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci U S A. 1997;94:6438–43.CrossRef

120.

Zhou YT, Shimabukuro M, Wang MY, Lee Y, Higa M, Milburn JL, et al. Role of peroxisome proliferatoractivated receptor a in disease of pancreatic b cells. Proc Natl Acad Sci U S A. 1998;95:8898–903.CrossRef

121.

Monga SPS, Cagle PT. Molecular Pathology of Liver Diseases (Molecular Pathology Library 5). US: Springer; 2011.

122.

Lin JD. The PGC-1 coactivator networks: chromatin-remodeling and mitochondrial energy metabolism. Mol Endocrinol. 2009;23:2–10.CrossRef

123.

Sawadogo M, Roeder RG. Interaction of a gene-specific transcription factor with the adenovirus major late promoter upstream of the TATA box region. Cell. 1985;43:165–75.CrossRef

124.

Carthew RW, Chodosh LA, Sharp PA. An RNA polymerase II transcription factor binds to an upstream element in the adenovirus major late promoter. Cell. 1985;43:439–48.CrossRef

125.

Sawadogo M, Van Dyke MW, Gregor PD, Roeder RG. Multiple forms of the human gene-specific transcription factor USF. I. Complete purification and identification of USF from HeLa cell nuclei. J Biol Chem. 1988;263:11985–93.

126.

Wang D, Sul HS. Upstream stimulatory factor binding to the E-box at -65 is required for insulin regulation of the fatty acid synthase promoter. J Biol Chem. 1997;272:26367–74.CrossRef

127.

Wang D, Sul HS. Upstream stimulatory factors bind to insulin response sequence of the fatty acid synthase promoter. J Biol Chem. 1995;270:28716–22.CrossRef

128.

Wong RH, Sul HS. DNA-PK: relaying the insulin signal to USF in lipogenesis. Cell Cycle. 2009;8:1973–8.CrossRef

129.

Bakan I, Laplante M. Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol. 2012;23:226–34.CrossRef

130.

Paulauskis JD, Sul HS. Cloning and expression of mouse fatty acid synthase and other specific mRNAs. Developmental and hormonal regulation in 3T3-L1 cells. J Biol Chem. 1988;263:7049–54.

131.

Latasa MJ, Moon YS, Kim KH, Sul HS. Nutritional regulation of the fatty acid synthase promoter in vivo: sterol regulatory element binding protein functions through an upstream region containing a sterol regulatory element. Proc Natl Acad Sci U S A. 2000;97:10619–24.CrossRef

132.

Wang D, Sul HS. Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway. Involvement of protein kinase B/Akt. J Biol Chem. 1998;273:25420–6.CrossRef

133.

Taniguchi CM, Emanuelli B, Kahn B. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.CrossRef

134.

Taniguchi CM, Kondo T, Sajan M, Luo J, Bronso R, Asano T, et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 2006;3:343–53.CrossRef

135.

Farese RV, Sajan MP, Standaert ML. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp Biol Med. 2005;230:593–605.

136.

Wong RH, Chang I, Hudak CS, Hyun S, Kwan HY, Sul HS. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell. 2009;136:1056–72.CrossRef

137.

Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000;6:77–86.CrossRef

138.

Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274:30028–32.CrossRef

139.

Latasa MJ, Griffin MJ, Moon YS, Kang C, Sul HS. Occupancy and function of the -150 sterol regulatory element and -65 E-box in nutritional regulation of the fatty acid synthase gene in living animals. Mol Cell Biol. 2003;23:5896–907.CrossRef

140.

Eyster KM. The membrane and lipids as integral participants in signal transduction: lipid signal transduction for the non-lipid biochemist. Adv Physiol Educ. 2007;31:5–16.CrossRef

141.

Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44.CrossRef

142.

Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.CrossRef

143.

Wang Y, Huang F. N-3 Polyunsaturated Fatty Acids and Inflammation in Obesity: Local Effect and Systemic Benefit. BioMed Res Int. 2015;2015(581469):16.

144.

Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45:592–601.CrossRef

Title: Role of BAF60a/BAF60c in chromatin remodeling and hepatic lipid metabolism
Authors: Ping Zhang
Lulu Li
Zhengxi Bao
Feiruo Huang
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Nutrition & Metabolism / Issue 1/2016
Electronic ISSN: 1743-7075
DOI: https://doi.org/10.1186/s12986-016-0090-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Postprandial lipemic and inflammatory responses to high-fat meals: a review of the roles of acute and chronic exercise

Effects of dietary fat subtypes on glucose homeostasis during pregnancy in rats

Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population

Weight restoration on a high carbohydrate refeeding diet promotes rapid weight regain and hepatic lipid accumulation in female anorexic rats

Heat-treated high-fat diet modifies gut microbiota and metabolic markers in apoe−/− mice

Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials